Infliximab for the treatment of active scleritis

Abstract

Objective-This study aimed to evaluate the possible safety and effectiveness of infliximab in patients with active scleritis.

Infliximab en pacientes con enfermedad ocular inflamatoria, refractarios a DARMES

“…Existen muchas series de casos en las que se describe los beneficios de infliximab en el tratamiento de AR, tanto para su compromiso articular como a nivel extraarticular, especialmente a nivel de la superficie ocular en casos refractarios a la terapia con DARMES tradicionales, incluido corticoides sisté-micos en dosis altas (6)(7)(8)13) . Lo destacable en el presente trabajo es el hallazgo en lo referido a la buena evolución del tejido injertado en el parche esclerocorneal, lo cual determinó una mejoría en la agudeza visual y se manifestó en la no necesidad de una nueva intervención quirúrgica hasta la publicación del presente artículo.…”

Does Cyclophosphamide Still Have a Role in the Treatment of Severe Inflammatory Eye Disease?

“…26 Commonly used agents include methotrexate, azathioprine, mycophenolate, and cyclosporine. 1 In addition, biological agents, particularly anti-TNF and anti-CD20 therapy, have been shown to be effective in the control of severe inflammatory eye diseases, such as Behçet disease, 27 scleritis, 28,29 and OCP. 30 However, there have been no comparative studies addressing the important issue of the relative efficacy of such therapy in comparison to cyclophosphamide in inducing disease remission.…”

Treatment and management of scleral disorders

“…75,143 In patients with anterior scleritis, therapy with infliximab, a chimeric human/murine monoclonal antibody to human TNF-α, was shown to help taper other immunosuppressives. 137 Cyclophosphamide can be used for the most severe cases of scleritis. A common dose is 2mg/kg/day with oral corticosteroids.…”